Intraoperative MRI and angiography confirms retinoblastoma chemotherapy treatment
June 19, 2013
/PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that
New Haven, CT
, neurosurgeons are confirming effective chemotherapy delivery in treating eye cancer using intraoperative imaging within the VISIUS
Selective intra-arterial chemotherapy is a growing strategy for treating retinoblastomas - a rapid growth cancer in the eye primarily affecting infants. The technique allows for delivery of an increased concentration of the drug directly to the tumor and reduces the need to use systemically delivered chemotherapy which can cause significant side effects.
Using the VISIUS Surgical Theatre with iMRI during the treatment procedure is a novel approach to this strategy that permits
neurosurgeons to confirm successful delivery of chemotherapy at the tumor site. "Combining the intraoperative MRI with biplane angiography has allowed us to rapidly acquire an intraoperative MRI and indirectly confirm that the chemotherapy reached the site of interest," said Dr.
Ketan R. Bulsara
, Associate Professor of Neurosurgery and Director of Neuroendovascular and Skull-Base Surgery at
Yale School of Medicine
. He believes Yale-New Haven Hospital is the first to use the iMRI for confirming this treatment method.
The VISIUS Surgical Theatre at Yale-New Haven Hospital features a high-field iMRI that moves between three rooms for diagnostic and surgical usage. Installed in 2010, the multi-disciplinary suite also has biplane angiography in the third room to add a true intraoperative imaging advantage to neurosurgical, endovascular and microsurgical operating capabilities. The VISIUS iMRI does not require the patient to be moved from the OR table to other rooms for scanning because the MR moves on ceiling rails, so optimum positioning for neurosurgery is never compromised and typical clinical workflow is not impacted.